Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01665768 · ClinicalTrials.gov registry record · Phase 2
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT01665768 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 56 participants.
The verdict
NCT01665768, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This research is being done to determine if combining an investigational drug called Everolimus with Rituximab can reduce the risk of your cancer from returning after high dose chemotherapy.
Interventions
- DRUG Everolimus
- BIOLOGICAL Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2012-09 |
| Est. Completion | 2020-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01665768
The ClinicalTrials.gov registry entry for NCT01665768 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT01665768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01665768 about?
NCT01665768 is a clinical study titled "Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma". This research is being done to determine if combining an investigational drug called Everolimus with Rituximab can reduce the risk of your cancer from returning after high dose chemotherapy.
What is the current status of trial NCT01665768?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2012-09. Estimated completion is 2020-08.
What interventions are being tested in trial NCT01665768?
The interventions under investigation include: Everolimus (DRUG), Rituximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01665768?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.